Subconjunctival Steroids for Conjunctival Benign Reactive Lymphoid Hyperplasia
Jai W Thompson1, Joseph Whitfield2, Lindsay A McGrath3,4
1Sunshine Coast University Hospital, Birtinya, QLD, Australia.
Ocular Oncology and Pathology
|July 7, 2025
Summary
Subconjunctival triamcinolone acetate effectively treated conjunctival benign reactive lymphoid hyperplasia (CBRLH), a rare condition. This approach led to complete lesion resolution and sustained remission in two patients, suggesting a potential standard of care.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Conjunctival benign reactive lymphoid hyperplasia (CBRLH) is a rare, benign lymphoproliferative disorder.
- Current treatment standards for CBRLH are not established, necessitating exploration of therapeutic options.
Purpose of the Study:
- To evaluate the efficacy of subconjunctival triamcinolone acetate in treating CBRLH.
- To present a case series demonstrating a novel therapeutic approach for CBRLH.
Main Methods:
- Two patients with CBRLH were treated with subconjunctival injections of triamcinolone acetate.
- Clinical and histological examinations were performed to diagnose and monitor the condition.
Main Results:
- Complete clinical resolution of CBRLH lesions was observed within three weeks post-treatment.
- No recurrence of lesions was noted during a 12-month follow-up period.
Conclusions:
- Subconjunctival triamcinolone acetate is an effective treatment for CBRLH.
- This therapeutic approach offers rapid and sustained resolution, potentially guiding future management strategies for CBRLH.
